Meridian Bioscience (VIVO) Income Statement

Click line-items for a historical chart and %

Net Sales	47M
COST OF SALES	17.28M
GROSS PROFIT	29.72M
Research and development	3.76M
Selling and marketing	8.13M
General and administrative	7.98M
European and global sales & marketing leadership reorganization
Bioline Group transaction costs
Total operating expenses	20.83M
OPERATING INCOME	8.9M
Interest income
Other, net	259K
Total other income (expense)	-143K
EARNINGS BEFORE INCOME TAXES
INCOME TAX PROVISION	3.26M
NET EARNINGS
BASIC EARNINGS PER COMMON SHARE	0.13
DILUTED EARNINGS PER COMMON SHARE	0.13
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	-84.07M
EFFECT OF DILUTIVE STOCK OPTIONS	-756K
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	-84.82M
Common share options	-897K
DIVIDENDS DECLARED PER COMMON SHARE	0.2

Entities mentioned with VIVO

View All Entities